AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6820075 — intervention group
Group type: EXPERIMENTAL
Intervention: Other clinical parameters (birth weight, gestational age, oxygen requirements, enteral nutritional intake, congenital anomalies, heart disease)
Number of subjects: 26
Study 31463257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg daily)
Number of subjects: 20
Study 31463257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28893220 — intervention group
Group type: EXPERIMENTAL
Intervention: GUS-7 evaluation by a trainee rheumatologist (TR)
Number of subjects: 85
Study 28893220 — intervention group
Group type: COMPARATOR
Intervention: GUS-7 evaluation by a senior rheumatologist (SR)
Number of subjects: 85
Study 28893220 — intervention group
Group type: EXPERIMENTAL
Intervention: GUS-7 usefulness rating by TR
Number of subjects: 85
Study 28893220 — intervention group
Group type: COMPARATOR
Intervention: GUS-7 usefulness rating by SR
Number of subjects: 85
Study 26821779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude mechanical stimulation (LMMS) - 10 minutes daily exposure at 30 Hz frequency, 0.3 g peak-to-peak acceleration.
Number of subjects: 138
Study 26821779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) - 10 minutes daily exposure, no mechanical stimulation.
Number of subjects: 138
Study 24980023 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-delivered basic (PB)
Number of subjects: 2004
Study 24980023 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-delivered environmental (PE)
Number of subjects: 2004
Study 24980023 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based basic (WB)
Number of subjects: 2004
Study 24980023 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based environmental (WE)
Number of subjects: 2004
Study 24980023 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2004
Study 22709997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire prevention education delivered by on-duty firefighters through door-to-door visits
Number of subjects: 18473
Study 22709997 — intervention group
Group type: COMPARATOR
Intervention: Cluster control group (no intervention)
Number of subjects: 18473
Study 20231743 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol counterirritant (2 ml applied to anterior knee)
Number of subjects: 30
Study 20231743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham counterirritant (2 ml applied to anterior knee)
Number of subjects: 30
Study 20231743 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study 18683490 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral probucol (250 mg daily)
Number of subjects: 0
Study 18683490 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol therapy for 7 days before and 6 months after coronary angioplasty
Number of subjects: 0
Study 15865268 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (random)
Number of subjects: 120
Study 15865268 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (required clinical culture)
Number of subjects: 120
Study 12060502 — intervention group
Group type: EXPERIMENTAL
Intervention: CPO/SA shampoo (1.5% ciclopirox olamine and 3% salicylic acid)
Number of subjects: 154
Study 12060502 — intervention group
Group type: COMPARATOR
Intervention: Nizoral (2.0% ketoconazole shampoo)
Number of subjects: 154
Study 10212737 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile convulsion group (n=57)
Number of subjects: 123
Study 10212737 — intervention group
Group type: COMPARATOR
Intervention: Non-febrile illness group (n=66)
Number of subjects: 123
Study 10212737 — intervention group
Group type: EXPERIMENTAL
Intervention: Social class differences
Number of subjects: 123
Study 10212737 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 123
Study 7818326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy (LA)
Number of subjects: 182
Study 7818326 — intervention group
Group type: COMPARATOR
Intervention: Lymph node sampling
Number of subjects: 182
Study 2089092 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72.974A (0.1-12 mg)
Number of subjects: 0
Study 848665 — intervention group
Group type: COMPARATOR
Intervention: Intraluminal administration of 5-fluorouracil (5-FU)
Number of subjects: 0
Study 848665 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 5-fluorouracil (5-FU)
Number of subjects: 0
Study 848665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramural administration of 5-fluorouracil (5-FU)
Number of subjects: 0
Study 848665 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) therapy (general)
Number of subjects: 0
Study 31744526 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Mozart's Sonata for two pianos in D major (K.448) during cannulation
Number of subjects: 120
Study 31744526 — intervention group
Group type: COMPARATOR
Intervention: White noise during cannulation
Number of subjects: 120
Study 31744526 — intervention group
Group type: COMPARATOR
Intervention: No-sound period (wearing only headphones) during cannulation
Number of subjects: 120
Study 28449281 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg varenicline
Number of subjects: 484
Study 28449281 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg varenicline
Number of subjects: 484
Study 25847552 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT+medication therapy
Number of subjects: 105
Study 23818409 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced movement therapy (kid‐CIMT)
Number of subjects: 47
Study 23818409 — intervention group
Group type: COMPARATOR
Intervention: Intensive bimanual training
Number of subjects: 47
Study 22008957 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula A (0.04% DHA)
Number of subjects: 42
Study 22008957 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula B (0.33% DHA)
Number of subjects: 42
Study 22008957 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula C (0.52% DHA)
Number of subjects: 42
Study 22008957 — intervention group
Group type: COMPARATOR
Intervention: Human Milk (HM) (0.51% AA, 0.38% DHA)
Number of subjects: 42
Study 19755935 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral in situ fusion (PLF)
Number of subjects: 380
Study 19755935 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral instrumented fusion with pedicle screws (PPS)
Number of subjects: 380
Study 19755935 — intervention group
Group type: EXPERIMENTAL
Intervention: PPS plus interbody fusion (360 degrees)
Number of subjects: 380
Study 19755935 — intervention group
Group type: COMPARATOR
Intervention: Decompression only without fusion
Number of subjects: 380
Study 17323661 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.1 ml/kg (Group NS)
Number of subjects: 48
Study 17323661 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 1.5 mg/kg (Group L)
Number of subjects: 48
Study 17323661 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg (Group R)
Number of subjects: 48
Study 14745674 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% cocaine
Number of subjects: 50
Study 14745674 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine
Number of subjects: 50
Study 11511427 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath isoprene production in patients with CHF
Number of subjects: 12
Study 11511427 — intervention group
Group type: COMPARATOR
Intervention: Breath isoprene production in healthy control subjects
Number of subjects: 12
Study 9591761 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (0.25 mg/kg bolus and 12-hour infusion of 10 microg/min, EPIC regimen)
Number of subjects: 41
Study 9591761 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (0.25 mg/kg bolus and 12-hour infusion of 0.125 microg x kg(‐1) x min(‐1), EPILOG regimen)
Number of subjects: 41
Study 8201150 — intervention group
Group type: EXPERIMENTAL
Intervention: KC‐764 10 mg/day
Number of subjects: 15
Study 8201150 — intervention group
Group type: EXPERIMENTAL
Intervention: KC‐764 20 mg/day
Number of subjects: 15
Study 8201150 — intervention group
Group type: EXPERIMENTAL
Intervention: KC‐764 40 mg/day
Number of subjects: 15
Study 8201150 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 15
Study 8201150 — intervention group
Group type: EXPERIMENTAL
Intervention: KC‐764 (all doses)
Number of subjects: 15
Study 3310633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g at night
Number of subjects: 66
Study 3310633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 30742513 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour simulation workshop using a medical foot-care model (n = 15)
Number of subjects: 29
Study 30742513 — intervention group
Group type: COMPARATOR
Intervention: 2-hour workshop on compression therapy (n = 14)
Number of subjects: 29
Study 28007137 — intervention group
Group type: EXPERIMENTAL
Intervention: HotBalloon ablation (HBA)
Number of subjects: 143
Study 28007137 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Number of subjects: 143
Study 25552616 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated access to a web-based brief intervention (BI) for risky drinkers delivered by primary healthcare professionals (PHCPs)
Number of subjects: 1000
Study 25552616 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face brief intervention (BI) by the practitioner
Number of subjects: 1000
Study 20074288 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized/wavefront guided ablation
Number of subjects: 34
Study 20074288 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 34
Study 20646431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Number of subjects: 134
Study 20646431 — intervention group
Group type: COMPARATOR
Intervention: Radical Nephrectomy
Number of subjects: 134
Study 20646431 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 134
Study 17613282 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDRA primary SOCs
Number of subjects: 355
Study 17613282 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIZE primary SOCs
Number of subjects: 355
Study 15855919 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle electrostimulation (MEST)
Number of subjects: 47
Study 15855919 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study 12585189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule (TXLC)
Number of subjects: 60
Study 12585189 — intervention group
Group type: COMPARATOR
Intervention: Composite Danshen tablet
Number of subjects: 60
Study 10516941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide nasal spray (200 micrograms per nostril)
Number of subjects: 24
Study 10516941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7492160 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-electrostatic spacer
Number of subjects: 124
Study 7492160 — intervention group
Group type: COMPARATOR
Intervention: Babyhaler
Number of subjects: 124
Study 7492160 — intervention group
Group type: COMPARATOR
Intervention: Nebuhaler
Number of subjects: 124
Study 7492160 — intervention group
Group type: COMPARATOR
Intervention: AeroChamber
Number of subjects: 124
Study 2038242 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive behavioral therapy
Number of subjects: 36
Study 2038242 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-based cognitive behavioral therapy
Number of subjects: 36
Study 2038242 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 36
Study 7011011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Motrin)
Number of subjects: 14
Study 7011011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 14
Study 7011011 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 14
Study 30474504 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) - 30 Gy in 5 nonconsecutive fractions
Number of subjects: 22
Study 30474504 — intervention group
Group type: COMPARATOR
Intervention: Whole breast irradiation - 50 Gy in 25 fractions plus 10 Gy in 5 fractions to the tumor bed
Number of subjects: 22
Study 28901831 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration between traditional healers, faith healers, and biomedical care providers
Number of subjects: 0
Study 28901831 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to collaboration
Number of subjects: 0
Study 28901831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways to better collaboration
Number of subjects: 0
Study 28901831 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared sense of responsibility for patient well-being
Number of subjects: 0
Study 24258063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tutoring (standard and nonstandard equations)
Number of subjects: 51
Study 24258063 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard equations tutoring
Number of subjects: 51
Study 24258063 — intervention group
Group type: COMPARATOR
Intervention: No-tutoring control
Number of subjects: 51
Study 24183563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 40 mg per day
Number of subjects: 199
Study 24183563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 24183563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 199
Study 22592354 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-to-goal (TTG): BI plus repeated demonstrations of inhaler use and participant comprehension assessments (teach-back)
Number of subjects: 50
Study 22592354 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (BI): single-set of verbal and written step-by-step instructions
Number of subjects: 50
Study 22592354 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-to-goal (TTG)
Number of subjects: 50
Study 22592354 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (BI)
Number of subjects: 50
Study 19697196 — intervention group
Group type: EXPERIMENTAL
Intervention: TW+ (teams that received extra training in specific teamwork behaviours)
Number of subjects: 4
Study 19697196 — intervention group
Group type: COMPARATOR
Intervention: TW- (teams that received only clinical training)
Number of subjects: 4
Study 19697196 — intervention group
Group type: EXPERIMENTAL
Intervention: TW+
Number of subjects: 4
Study 19697196 — intervention group
Group type: COMPARATOR
Intervention: TW-
Number of subjects: 4
Study 17039354 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet
Number of subjects: 10
Study 17039354 — intervention group
Group type: COMPARATOR
Intervention: Facial mask
Number of subjects: 10
Study 14694173 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdialysis urea rebound measured using 30-min and 60-min postdialysis samples.
Number of subjects: 1245
Study 14694173 — intervention group
Group type: EXPERIMENTAL
Intervention: K/V as a predictor of rebound.
Number of subjects: 1245
Study 14694173 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with greater rebound in patients using AV accesses or venous catheters.
Number of subjects: 1245
Study 14694173 — intervention group
Group type: EXPERIMENTAL
Intervention: Equations of the form eKt/V = single‐pool Kt/V - B x (K/V).
Number of subjects: 1245
Study 14694173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate equation slope coefficients for K/V.
Number of subjects: 1245
Study 11509518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological melatonin levels
Number of subjects: 16
Study 11509518 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressed melatonin
Number of subjects: 16
Study 11509518 — intervention group
Group type: COMPARATOR
Intervention: Normal endogenous melatonin levels
Number of subjects: 16
Study 9564797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg total daily dose
Number of subjects: 473
Study 9564797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg total daily dose
Number of subjects: 473
Study 9564797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg total daily dose
Number of subjects: 473
Study 9564797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg total daily dose
Number of subjects: 473
Study 9564797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 9564797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (all doses)
Number of subjects: 473
Study 8043333 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 13
Study 8043333 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular pacing
Number of subjects: 13
Study 8043333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 13
Study 2500670 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35-140 mcg (acute)
Number of subjects: 22
Study 2500670 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 mcg or 70 mcg BID (chronic)
Number of subjects: 22
Study 2500670 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chronic)
Number of subjects: 22
Study 29264999 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 100
Study 29264999 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 100
Study 29264999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DCB and PTA
Number of subjects: 100
Study 27776622 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week yoga intervention (n = 40)
Number of subjects: 60
Study 27776622 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (n = 20)
Number of subjects: 60
Study 25382609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone
Number of subjects: 45
Study 22784037 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tenofovir (TDF)
Number of subjects: 4747
Study 22784037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tenofovir‐emtricitabine (TDF‐FTC)
Number of subjects: 4747
Study 22784037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4747
Study 20410374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-assisted emotional disclosure (CAED)
Number of subjects: 28
Study 20410374 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 28
Study 18639205 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt needles
Number of subjects: 438
Study 18639205 — intervention group
Group type: COMPARATOR
Intervention: Sharp needles
Number of subjects: 438
Study 14594860 — intervention group
Group type: EXPERIMENTAL
Intervention: +GH (0.4 IU GH)
Number of subjects: 8
Study 14594860 — intervention group
Group type: COMPARATOR
Intervention: -GH
Number of subjects: 8
Study 14594860 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects, n = 8, mean age = 40.4 +/- 4.2 yr)
Number of subjects: 8
Study 12678539 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate ointment (0.2% twice daily) applied to the perianal area
Number of subjects: 20
Study 12678539 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied to the perianal area
Number of subjects: 20
Study 9743392 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole 15 microg/kg
Number of subjects: 14
Study 9743392 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole 50 microg/kg
Number of subjects: 14
Study 9743392 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole 150 microg/kg
Number of subjects: 14
Study 9743392 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 14
Study 11271207 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 540
Study 3191944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 25 mg
Number of subjects: 10
Study 3191944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 10
Study 3191944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 75 mg
Number of subjects: 10
Study 3191944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 10
Study 3191944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31841037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation during exercise sessions
Number of subjects: 18
Study 31841037 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation during exercise sessions
Number of subjects: 18
Study 31707824 — intervention group
Group type: EXPERIMENTAL
Intervention: High ordering cardiologists (top tertile of transthoracic echocardiograms)
Number of subjects: 3966
Study 31707824 — intervention group
Group type: COMPARATOR
Intervention: Low ordering cardiologists (low tertile of transthoracic echocardiograms)
Number of subjects: 3966
Study 28855179 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP+FC (face cooling with ice water at 0±0°C)
Number of subjects: 10
Study 28855179 — intervention group
Group type: COMPARATOR
Intervention: LBNP+Sham (thermoneutral water at 34±1°C)
Number of subjects: 10
Study 25457977 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulative therapy (MT) plus rehabilitation
Number of subjects: 33
Study 25457977 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 33
Study 23237514 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-stretch mark cream containing hydroxyprolisilane-C, rosehip oil, Centella asiatica triterpenes and vitamin E
Number of subjects: 100
Study 23237514 — intervention group
Group type: COMPARATOR
Intervention: Control group (cream without active ingredients)
Number of subjects: 100
Study 21529979 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Glutamic Acid Decarboxylase Antibody (GADA) testing
Number of subjects: 0
Study 19896601 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction curettage
Number of subjects: 1320
Study 19896601 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 1320
Study 19896601 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction curettage and Conventional procedure
Number of subjects: 1320